Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 2193432, 12 pages
Review Article

Endothelial Progenitor Cells for Ischemic Stroke: Update on Basic Research and Application

1Department of Neurology, People’s Liberation Army 152 Hospital, Pingdingshan, Henan 467000, China
2Department of Neurology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
3Department of Neurology, General Hospital of Jinan Military Region, Jinan, Shandong 250031, China

Correspondence should be addressed to Zhenhua Zhou; moc.621@100retiolpxe

Received 16 May 2017; Accepted 3 July 2017; Published 16 August 2017

Academic Editor: Yao Li

Copyright © 2017 Shaohua Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Ischemic stroke is one of the leading causes of human death and disability worldwide. So far, ultra-early thrombolytic therapy is the most effective treatment. However, most patients still live with varying degrees of neurological dysfunction due to its narrow therapeutic time window. It has been confirmed in many studies that endothelial progenitor cells (EPCs), as a kind of adult stem cells, can protect the neurovascular unit by repairing the vascular endothelium and its secretory function, which contribute to the recovery of neurological function after an ischemic stroke. This paper reviews the basic researches and clinical trials of EPCs especially in the field of ischemic stroke and addresses the combination of EPC application with new technologies, including neurovascular intervention, synthetic particles, cytokines, and EPC modification, with the aim of shedding some light on the application of EPCs in treating ischemic stroke in the future.